aTyr Pharma, Inc.

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine / Montefiore Einstein to advance development and testing of ATYR2810, its anti-NRP2 monoclonal antibody, in pediatric osteosarcoma. The collaboration is led by Dr. Bang H. Hoang, whose research focuses on NRP2's role in bone and soft tissue cancers; ATYR2810 has shown anti-tumor effects in preclinical models across multiple tumor types and has completed GLP toxicology and cGMP manufacturing. No financial terms were disclosed and the asset remains preclinical, so the news is an early-stage pipeline signal rather than a near-term catalyst; aTyr's lead clinical asset remains efzofitimod for interstitial lung disease.

•13d ago

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

aTyr Pharma published data in the Journal of Biological Chemistry demonstrating anti-fibrotic effects of ATYR0101, a DARS-derived fusion protein that targets LTBP-1 to induce myofibroblast apoptosis. In an in vivo bleomycin lung fibrosis model, ATYR0101 significantly reduced collagen content and Ashcroft score, outperforming the marketed anti-fibrotic nintedanib used as a control. ATYR0101 remains preclinical, in IND-enabling studies with expected clinic entry in 2027; the news is scientific validation rather than a near-term catalyst, with lead candidate efzofitimod unchanged in development for interstitial lung disease.

•19d ago

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in chronic pulmonary sarcoidosis with restrictive lung disease, with study activities expected to begin in Q4 2026. The global, randomized, placebo-controlled 54-week trial will enroll up to approximately 372 patients, using FVC change at week 48 as the primary endpoint, focusing on the restrictive subgroup that showed clinically meaningful benefit in the prior Phase 3 EFZO-FIT study. The company notes future development will require additional capital through equity or debt offerings, partnerships, or licensing — a funding overhang alongside the execution risk of the new trial.

•1mo ago

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma anticipates receiving a response from the FDA by mid-September 2026 regarding the protocol for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis. The planned global trial will enroll approximately 372 patients in a 54-week, randomized, double-blind, placebo-controlled study. Efzofitimod is a novel biologic immunomodulator currently also being investigated in a Phase 2 study for systemic sclerosis-related ILD.

•2mo ago

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma announced that a subgroup analysis of the Phase 3 EFZO-FIT study showed patients with restrictive lung disease experienced a clinically meaningful benefit in lung function when treated with efzofitimod. The post-hoc analysis of 44 patients demonstrated a placebo-adjusted improvement in FVC of 123.8 ml at week 48 for the 5.0 mg/kg dose, alongside positive trends in patient-reported outcomes. Based on these findings, the company submitted a protocol to the FDA in June 2026 for a planned Phase 3 study targeting this specific patient population.

•3mo ago

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma reported Q1 2026 results with a net loss of $10.8 million, a significant improvement from the $14.9 million loss in the same period last year, driven by lower R&D and G&A expenses. The company ended the quarter with $68.3 million in cash and investments, providing a runway for continued development activities. Following a Type C meeting with the FDA, aTyr outlined a clear path forward for its lead asset efzofitimod in pulmonary sarcoidosis, planning to submit an IND in June 2026 for a new Phase 3 study utilizing FVC as the primary endpoint. Enrollment in the Phase 2 EFZO-CONNECT study for SSc-ILD is on track to complete in the first half of 2026, and a poster for preclinical candidate ATYR0101 was accepted for presentation at the Extracellular Matrix Pharmacology Congress in June.

•5mo ago

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma received positive feedback from the FDA on the path forward for efzofitimod in pulmonary sarcoidosis. The company plans to submit an IND in June 2026 for a new Phase 3 study, focusing on patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The primary endpoint will be change from baseline in FVC at week 48, and the key secondary endpoint will be change from baseline in the KSQ-Lung score at week 48. aTyr will host a conference call and webcast today at 4:30pm ET / 1:30pm PT to discuss the regulatory and clinical update.

•5mo ago